Showing 1 - 20 results of 77,778 for search '(( significant ns based ) OR ( significant ((we decrease) OR (a decrease)) ))', query time: 2.14s Refine Results
  1. 1

    A randomized trial of a behavioral intervention to decrease hospital length of stay by decreasing bedrest by Juliana Tolles (8282265)

    Published 2020
    “…Previous studies of early mobilization have demonstrated improvement in outcomes, but the interventions studied have been resource-intensive. We aimed to decrease the time hospital inpatients spend in bed through a pragmatic mobilization protocol.…”
  2. 2
  3. 3
  4. 4
  5. 5

    Dynorphin Neuropeptides Decrease Apparent Proton Affinity of ASIC1a by Occluding the Acidic Pocket by Lilia Leisle (11356934)

    Published 2021
    “…Prolonged acidosis, as it occurs during ischemic stroke, induces neuronal death via acid-sensing ion channel 1a (ASIC1a). Concomitantly, it desensitizes ASIC1a, highlighting the pathophysiological significance of modulators of ASIC1a acid sensitivity. …”
  6. 6

    Dynorphin Neuropeptides Decrease Apparent Proton Affinity of ASIC1a by Occluding the Acidic Pocket by Lilia Leisle (11356934)

    Published 2021
    “…Prolonged acidosis, as it occurs during ischemic stroke, induces neuronal death via acid-sensing ion channel 1a (ASIC1a). Concomitantly, it desensitizes ASIC1a, highlighting the pathophysiological significance of modulators of ASIC1a acid sensitivity. …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx by Le Zhang (88249)

    Published 2025
    “…Additionally, a significant correlation between Chl-a concentration and SSC was found. …”
  13. 13
  14. 14
  15. 15
  16. 16

    GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage by Wieslaw M. Kazmierski (1706686)

    Published 2020
    “…The discovery of GSK2818713 (<b>13</b>), a nonstructural protein 5A (NS5A) HCV inhibitor characterized by a significantly improved genotype coverage relative to first-generation NS5A inhibitor daclatasvir (DCV), is detailed herein. …”
  17. 17
  18. 18
  19. 19
  20. 20